HEADACHE/MIGRAINE

A 75 mg orally dissolving tablet formulation of the calcitonin gene-related peptide receptor antagonist met both co-primary end points of freedom from the patient-indicated most bothersome symptom and freedom from pain at 2 hours.

SAP Partner Banner

About NeurologyLive's Headache & Migraine Clinical Focus page:

The NeurologyLive Headache & Migraine Clinical Focus page serves as a hub for breaking news, videos, and other resources. Items covered here include updates from the most-attended neurological conferences and annual meetings via articles and video interviews with neurology’s leading experts and key opinion leaders.
 
This page will always be up-to-date, providing breaking news coverage of U.S. Food and Drug Administration (FDA) approvals, key takeaways from the latest clinical trials, and notifications of recent updates to clinical guidelines for headaches and migraines. Additionally, this Clinical Focus page provides an array of condition-specific resources, like information on new and emerging therapies for migraine relief and prevention.